A Phase 1 Safety, Pharmacokinetic, and Immunologic Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2017
At a glance
- Drugs FLT-3 ligand (Primary)
- Indications B cell lymphoma; Malignant melanoma
- Focus Therapeutic Use
- 02 Nov 2012 Celldex intends to report results at the American Society of Hematology (ASH) Annual Meeting in December 2012.
- 02 Nov 2012 Status changed from active, no longer recruiting to completed, as reported in a Celldex media release.
- 28 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.